A New Hope in Alzheimer’s Prevention
A promising experimental treatment called gantenerumab may significantly delay the onset of Alzheimer’s symptoms, according to a new international study. For people with a genetic predisposition, the drug could cut the risk of developing symptoms by half.
What Is Gantenerumab?
Gantenerumab is a monoclonal antibody developed by Roche that targets and removes beta-amyloid plaques, one of the main biological markers linked to Alzheimer’s disease.
Unlike earlier drugs that only relieved symptoms like memory loss or behavioral issues, this new generation of treatments aims to slow or prevent disease progression at its root.
A Study Focused on Genetic Alzheimer’s
Although hereditary Alzheimer’s is rare (less than 1% of cases), it allows researchers to test drugs before symptoms appear. The DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit) has been running trials since 2012 on people with rare genetic mutations (APP, PSEN1, PSEN2).
In a recent 3-year open-label extension study, 73 participants from 8 countries received increasing doses of gantenerumab. These participants were already involved in a previous clinical trial.
Encouraging Results Despite Roche Ending the Program
Even though Roche stopped development of gantenerumab in 2023 due to modest clinical results, this latest study, published in The Lancet Neurology, revealed promising data:
- Patients treated for up to eight years had their risk of symptoms reduced by 50%.
- Gantenerumab helped reduce amyloid plaques significantly.
- There were no serious side effects or deaths, although some participants experienced mild brain abnormalities (ARIA) or micro-bleeds.
A Potential Strategy to Delay Alzheimer’s
The researchers believe that long-term treatment, started early, could significantly delay or even prevent the onset of dementia in high-risk individuals. This marks a potential paradigm shift in how Alzheimer’s may be managed in the future.
